HUE047767T2 - Macitentánt tartalmazó terápiás készítmények - Google Patents
Macitentánt tartalmazó terápiás készítményekInfo
- Publication number
- HUE047767T2 HUE047767T2 HUE17191033A HUE17191033A HUE047767T2 HU E047767 T2 HUE047767 T2 HU E047767T2 HU E17191033 A HUE17191033 A HU E17191033A HU E17191033 A HUE17191033 A HU E17191033A HU E047767 T2 HUE047767 T2 HU E047767T2
- Authority
- HU
- Hungary
- Prior art keywords
- preparations containing
- therapeutic preparations
- containing macitentan
- macitentan
- therapeutic
- Prior art date
Links
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 title 1
- 229960001039 macitentan Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2008053252 | 2008-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE047767T2 true HUE047767T2 (hu) | 2020-05-28 |
Family
ID=41346591
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17191033A HUE047767T2 (hu) | 2008-08-13 | 2009-08-12 | Macitentánt tartalmazó terápiás készítmények |
| HUE09786912A HUE036071T2 (hu) | 2008-08-13 | 2009-08-12 | Macitentánt tartalmazó terápiás készítmények |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE09786912A HUE036071T2 (hu) | 2008-08-13 | 2009-08-12 | Macitentánt tartalmazó terápiás készítmények |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8809334B2 (enEXAMPLES) |
| EP (2) | EP3300729B1 (enEXAMPLES) |
| JP (3) | JP5764061B2 (enEXAMPLES) |
| KR (1) | KR101678699B1 (enEXAMPLES) |
| CN (1) | CN102099026B (enEXAMPLES) |
| AR (1) | AR073031A1 (enEXAMPLES) |
| AU (1) | AU2009280843B2 (enEXAMPLES) |
| BR (1) | BRPI0917661B8 (enEXAMPLES) |
| CA (1) | CA2731370C (enEXAMPLES) |
| CY (2) | CY1119826T1 (enEXAMPLES) |
| DK (2) | DK2315587T3 (enEXAMPLES) |
| ES (2) | ES2763176T3 (enEXAMPLES) |
| HK (1) | HK1253355B (enEXAMPLES) |
| HR (2) | HRP20171917T1 (enEXAMPLES) |
| HU (2) | HUE047767T2 (enEXAMPLES) |
| IL (1) | IL211143A0 (enEXAMPLES) |
| LT (2) | LT3300729T (enEXAMPLES) |
| MA (1) | MA32614B1 (enEXAMPLES) |
| MX (1) | MX350011B (enEXAMPLES) |
| MY (1) | MY178894A (enEXAMPLES) |
| NO (1) | NO2315587T3 (enEXAMPLES) |
| NZ (1) | NZ591601A (enEXAMPLES) |
| PL (2) | PL2315587T3 (enEXAMPLES) |
| PT (2) | PT2315587T (enEXAMPLES) |
| RU (1) | RU2519161C2 (enEXAMPLES) |
| SI (2) | SI3300729T1 (enEXAMPLES) |
| SM (2) | SMT201900740T1 (enEXAMPLES) |
| TW (1) | TWI446911B (enEXAMPLES) |
| WO (1) | WO2010018549A2 (enEXAMPLES) |
| ZA (1) | ZA201101900B (enEXAMPLES) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1928409T3 (pl) | 2005-09-12 | 2013-02-28 | Actelion Pharmaceuticals Ltd | Trwała kompozycja farmaceutyczna zawierająca pirymidynosulfamid |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| ES2817557T3 (es) * | 2008-02-28 | 2021-04-07 | Nippon Shinyaku Co Ltd | Inhibidor de fibrosis |
| ES2763176T3 (es) | 2008-08-13 | 2020-05-27 | Actelion Pharmaceuticals Ltd | Composiciones terapéuticas que contienen macitentan |
| US9371264B2 (en) | 2013-01-11 | 2016-06-21 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9794795B1 (en) | 2016-04-29 | 2017-10-17 | Corning Optical Communications Wireless Ltd | Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS |
| WO2018112258A1 (en) | 2016-12-14 | 2018-06-21 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
| KR20240119159A (ko) * | 2018-09-14 | 2024-08-06 | 파모사 바이오팜 인코포레이티드 | 약산성 약물의 방출 제어를 위한 약제학적 조성물 및 이의 용도 |
| FI3897646T3 (fi) * | 2018-12-21 | 2024-06-26 | Actelion Pharmaceuticals Ltd | Masitentaani keuhkovaltimoverenpainetaudin hoitoon |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| WO2021105331A1 (en) | 2019-11-29 | 2021-06-03 | Actelion Pharmaceuticals Ltd | Methods of treating pulmonary arterial hypertension |
| CA3161960A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) |
| US20250064799A1 (en) | 2021-12-31 | 2025-02-27 | Tenax Therapeutics, Inc. | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1097239A (en) | 1976-05-11 | 1981-03-10 | Salvador Moncada | Enzymatic preparation of prostacyclin and its salts |
| DE2845770A1 (de) | 1978-10-19 | 1980-04-30 | Schering Ag | Neue prostacyclin-derivate und verfahren zu ihrer herstellung |
| JPS58124778A (ja) | 1982-01-20 | 1983-07-25 | Toray Ind Inc | ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体 |
| US4683330A (en) * | 1984-03-08 | 1987-07-28 | The Upjohn Company | Interphenylene carbacyclin derivatives |
| AU2002227984B8 (en) * | 2000-12-18 | 2007-01-04 | Actelion Pharmaceuticals Ltd. | Novel sulfamides and their use as endothelin receptor antagonists |
| SK8192003A3 (en) * | 2000-12-19 | 2003-10-07 | Merck Patent Gmbh | Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| DE10100426B4 (de) | 2001-01-08 | 2006-04-06 | Steag Hamatech Ag | Verfahren und Vorrichtung zum Zusammenfügen von Substraten |
| TWI316055B (enEXAMPLES) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| WO2004017993A1 (en) * | 2002-08-12 | 2004-03-04 | Actelion Pharmaceuticals Ltd | Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension |
| ES2320649T3 (es) * | 2002-12-02 | 2009-05-27 | Actelion Pharmaceuticals Ltd. | Pirimidin-sulfamidas y su uso como antagonistas de receptores de endotelina. |
| US20050101608A1 (en) * | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| TW200628467A (en) * | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
| PL1928409T3 (pl) * | 2005-09-12 | 2013-02-28 | Actelion Pharmaceuticals Ltd | Trwała kompozycja farmaceutyczna zawierająca pirymidynosulfamid |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| KR20100132489A (ko) * | 2008-02-20 | 2010-12-17 | 액테리온 파마슈티칼 리미티드 | 난소암을 치료하기 위하여 파클리탁셀을 포함하는 조합 |
| ES2763176T3 (es) | 2008-08-13 | 2020-05-27 | Actelion Pharmaceuticals Ltd | Composiciones terapéuticas que contienen macitentan |
-
2009
- 2009-08-12 ES ES17191033T patent/ES2763176T3/es active Active
- 2009-08-12 EP EP17191033.4A patent/EP3300729B1/en not_active Revoked
- 2009-08-12 US US13/058,639 patent/US8809334B2/en active Active
- 2009-08-12 WO PCT/IB2009/053553 patent/WO2010018549A2/en active Application Filing
- 2009-08-12 DK DK09786912.7T patent/DK2315587T3/en active
- 2009-08-12 NZ NZ591601A patent/NZ591601A/xx unknown
- 2009-08-12 SI SI200932016T patent/SI3300729T1/sl unknown
- 2009-08-12 AR ARP090103113A patent/AR073031A1/es not_active Application Discontinuation
- 2009-08-12 PL PL09786912T patent/PL2315587T3/pl unknown
- 2009-08-12 LT LTEP17191033.4T patent/LT3300729T/lt unknown
- 2009-08-12 PT PT97869127T patent/PT2315587T/pt unknown
- 2009-08-12 SI SI200931770T patent/SI2315587T1/en unknown
- 2009-08-12 EP EP09786912.7A patent/EP2315587B1/en not_active Revoked
- 2009-08-12 JP JP2011522608A patent/JP5764061B2/ja not_active Expired - Fee Related
- 2009-08-12 ES ES09786912.7T patent/ES2652590T3/es active Active
- 2009-08-12 HU HUE17191033A patent/HUE047767T2/hu unknown
- 2009-08-12 HU HUE09786912A patent/HUE036071T2/hu unknown
- 2009-08-12 NO NO09786912A patent/NO2315587T3/no unknown
- 2009-08-12 PT PT171910334T patent/PT3300729T/pt unknown
- 2009-08-12 BR BRPI0917661A patent/BRPI0917661B8/pt not_active IP Right Cessation
- 2009-08-12 RU RU2011109084/15A patent/RU2519161C2/ru active
- 2009-08-12 MY MYPI2011000637A patent/MY178894A/en unknown
- 2009-08-12 AU AU2009280843A patent/AU2009280843B2/en active Active
- 2009-08-12 KR KR1020117003547A patent/KR101678699B1/ko active Active
- 2009-08-12 LT LTEP09786912.7T patent/LT2315587T/lt unknown
- 2009-08-12 SM SM20190740T patent/SMT201900740T1/it unknown
- 2009-08-12 SM SM20170592T patent/SMT201700592T1/it unknown
- 2009-08-12 HR HRP20171917TT patent/HRP20171917T1/hr unknown
- 2009-08-12 PL PL17191033T patent/PL3300729T3/pl unknown
- 2009-08-12 TW TW098127151A patent/TWI446911B/zh active
- 2009-08-12 MX MX2011001625A patent/MX350011B/es active IP Right Grant
- 2009-08-12 CA CA2731370A patent/CA2731370C/en active Active
- 2009-08-12 DK DK17191033.4T patent/DK3300729T3/da active
- 2009-08-12 CN CN2009801279936A patent/CN102099026B/zh not_active Expired - Fee Related
-
2011
- 2011-02-10 IL IL211143A patent/IL211143A0/en active IP Right Grant
- 2011-03-07 MA MA33675A patent/MA32614B1/fr unknown
- 2011-03-11 ZA ZA2011/01900A patent/ZA201101900B/en unknown
-
2014
- 2014-07-18 US US14/335,657 patent/US9173881B2/en active Active
-
2015
- 2015-06-12 JP JP2015119021A patent/JP5956026B2/ja active Active
- 2015-06-12 JP JP2015119020A patent/JP5956025B2/ja active Active
- 2015-10-02 US US14/873,787 patent/US9597331B2/en active Active
-
2018
- 2018-01-19 CY CY20181100074T patent/CY1119826T1/el unknown
- 2018-10-03 HK HK18112650.6A patent/HK1253355B/en not_active IP Right Cessation
-
2019
- 2019-12-06 HR HRP20192204TT patent/HRP20192204T1/hr unknown
-
2020
- 2020-01-08 CY CY20201100016T patent/CY1122641T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262567B (en) | Concentrated therapeutic phospholipid compositions | |
| HUS1800016I1 (hu) | Fungicid készítmények | |
| HUE047767T2 (hu) | Macitentánt tartalmazó terápiás készítmények | |
| BRPI0916931A2 (pt) | agentes terapêuticos | |
| BRPI0914155A2 (pt) | preparações de xampu | |
| EP2296593A4 (en) | MEDICAL HEAD COVER | |
| BRPI0912213A2 (pt) | preparação cosmética | |
| BRPI0920521A2 (pt) | combinação farmacêutica | |
| HUE037163T2 (hu) | Hemoglobin készítmények | |
| BR112012004546A2 (pt) | "terapêutica por proteínas ligantes dll4-ligantes" | |
| PL2452709T3 (pl) | Kaniula | |
| DK2144905T3 (da) | Terapeutiske midler | |
| EP2052011A4 (en) | TARGETED THERAPEUTIC AGENT POLYLYSIN DENDRIMER | |
| BRPI0914152A2 (pt) | preparações de xampu | |
| DK2114993T3 (da) | Vaccine | |
| DK2035369T3 (da) | Terapeutiske | |
| EP2236149A4 (en) | MEDICAL COMPOSITION | |
| BRPI0921654A2 (pt) | formulação farmacêutica | |
| BRPI0921947A2 (pt) | formulações de proteína terapêutica | |
| BRPI1005433A2 (pt) | preparações farmacêuticas transdérmicas | |
| BRPI0820410A2 (pt) | Lactans substituídos terapêuticos | |
| DK2271618T3 (da) | Farmaceutiske forbindelser | |
| SMT201600041B (it) | Agenti terapeutici 713 | |
| BRPI0818598A2 (pt) | agentes terapêuticos - 802 | |
| HRP20160577T1 (hr) | Liječenje osteoartritisa |